Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v12-FR | Version v7-FR | |
|---|---|---|
| Language | French | French |
| Date Updated | 2023-11-17 | 2023-09-22 |
| Drug Identification Number | 02510170 | 02510170 |
| Brand name | XARELTO | XARELTO |
| Common or Proper name | Rivaroxaban | Rivaroxaban |
| Company Name | BAYER INC | BAYER INC |
| Ingredients | RIVAROXABAN | RIVAROXABAN |
| Strength(s) | 103.4MG | 103.4MG |
| Dosage form(s) | GRANULES FOR SUSPENSION | GRANULES FOR SUSPENSION |
| Route of administration | ORAL | ORAL |
| Packaging size | 250 mL bottle | 250 mL bottle |
| ATC code | B01AF | B01AF |
| ATC description | ANTITHROMBOTIC AGENTS | ANTITHROMBOTIC AGENTS |
| Reason for shortage | Shortage of an inactive ingredient or component. | Shortage of an inactive ingredient or component. |
| Anticipated start date | 2023-09-22 | 2023-09-22 |
| Actual start date | 2023-09-22 | |
| Estimated end date | 2023-11-17 | 2023-10-31 |
| Actual end date | 2023-11-16 | |
| Shortage status | Resolved | Anticipated shortage |
| Tier 3 Status | No | No |
| Company comments | ||
| Health Canada comments |